Rhaeos, Inc. Raises $2.2 Million in Oversubscribed Seed Round

Rhaeos, Inc., a private, clinical-stage medical device company developing a platform wireless and non-invasive wearable sensor initially targeting the neurosurgical suite, today announced the successful closing of its oversubscribed $2.2 million seed financing. The round, which brings a total of over $8 million in dilutive and non-dilutive financing to date, includes participation from Creative Ventures, Portal Innovations, Lateral Capital, Cedars-Sinai Accelerator, Kyto Life Science and Technology, Band of Angels, Northwestern University’s NXT Fund, University of Michigan Social Venture Fund, and private investors.

“This financing milestone is one of many achieved by Rhaeos this year. The elegant design of their sensor and approach to commercialization led by a team of experts in their respective fields are among the reasons why we invested in Rhaeos. The FlowSense™ platform has the potential to disrupt the wearable medical device space and we are glad to be a part of Rhaeos’ journey,” said Kulika Weizman, Principal at Creative Ventures.

The closing of the financing round adds to recent milestones the company accomplished including receiving $4M in grant funding from the NIH, completing the Cedars-Sinai Accelerator program, and initiating their FDA pivotal study. Proceeds will be used to prepare for the 2022 commercial launch of FlowSense™, the company’s first product.

Anna Lisa Somera and Dr. John Rogers are prolific leaders in the Chicago life science ecosystem. They along with the rest of the Rhaeos team have the capabilities and expertise to commercialize the FlowSense™ platform to help improve the lives of the millions of patients living with hydrocephalus and other chronic conditions,” said John Flavin, Founder and CEO of Portal Innovations.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

By using this website you agree to accept Medical Device News Magazine Privacy Policy